The National Institutes of Health (NIH) issued two requests for letters of interest (LOIs): 1) LOIs for National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH); and 2) LOIs for pediatric-focused NCI-MATCH. The NCI is launching a successor precision medicine trial to its NCI-MATCH, entitled NCI-ComboMATCH, with the purpose of overcoming drug resistance to single-agent therapy by developing genomically-directed targeted agent combinations.
Specifically, the NCI is soliciting LOIs from Clinical Laboratory Improvements Program (CLIA) certified laboratories that test tumor specimens from adult patients and pediatric patients utilizing Next-Generation Sequencing (NGS) assays to participate in the NCI-ComboMATCH trial.
Details on requirements candidates laboratories must meet to apply can be found on pages 4 through 7.
Letters of interest are due June 30.